Price movement over the last 24 hours
Adecoagro SA vs Eli Lilly And Co — how do they compare? Adecoagro SA trades at $10.12 (market cap $1.39B), while Eli Lilly And Co trades at $1,229.54 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 791.4× Adecoagro SA's market cap, and Adecoagro SA pays the higher dividend (3.08%). Which is the better fit depends on your goals.
| AGRO | LLY | |
|---|---|---|
Market Cap | $1.39B | $1.10T |
Sector | Technology | Health |
52-Week High | $15.25 | $1.24K |
52-Week Low | $7.13 | $625.65 |
Enterprise Value | $3.42B | $1.14T |
Dividend Yield | 3.08% | 0.56% |
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.48, down 1.66% today, with a bearish technical signal despite neutral oscillators. The company reported mixed quarterly results, missing Q1 2026 EPS estimates but showing strong adjusted EBITDA growth. Valuation metrics appear attractive with P/S of 0.71 and P/B of 0.78, though profitability remains weak with a 0.91% net margin. Recent news highlights innovation in agriculture operations and a declared $0.12 dividend for H1 2026.
The stock offers value appeal with below-market multiples and analyst consensus target of $12.75 implying 34% upside. However, inconsistent earnings performance and negative net income in 2025 pose execution risks. The bearish technical trend and competitive pressures in sustainable agriculture require careful monitoring for potential investors.
Eli Lilly (LLY) trades at $1,235.56, up 2.07% today, with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. Revenue surged to $65.18B in 2025, with a net income margin of 34.99%, while analyst consensus is strongly positive with a $1,310 price target. Recent news highlights expansion in China for its breast cancer drug and bullish commentary from financial media on growth prospects.
The outlook remains favorable due to robust revenue growth and high profitability, though elevated valuation ratios and regulatory risks pose challenges. Upside is supported by analyst optimism and institutional interest, but investors should monitor competitive pressures and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →